At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
PF-04447943 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects
In Brief
A Phase 1 clinical trial evaluating PF-04447943, Placebo, and 1 other intervention for Healthy. Completed, enrolled 44 participants across 1 site.
Detailed Summary
This is a study designed to ascertain the effect of PF-04447943 on QT interval in healthy adult subjects. This is conducted as part of standard drug development.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJun 2016
Primary CompletionOct 2016
TodayJul 2026
First PostedMay 30, 2016
Enrollment StartJun 29, 2016
Primary CompletionOct 20, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.1 years ago
Interventions
PF-04447943drug
Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
Placebodrug
Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
Moxifloxacindrug
Single oral dose of moxifloxacin administered as tablet